AB0985 The Influence of Etanercept on Inflammation Markers and Lipid Profile in Patients with Juvenile Idiopathic Arthritis

AB0985 The Influence of Etanercept on Inflammation Markers and Lipid Profile in Patients with Juvenile Idiopathic Arthritis

BackgroundChronic inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus had been proven to have a higher risk of atherosclerosis and premature coronary artery disease. On the other hand, the role of inflammation on dyslipidemia in patients with juvenile idiopathic arthriti...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2015-06, Vol.74 (Suppl 2), p.1228-1228
Hauptverfasser: Basic, J., Vojinovic, J., Susic, G., Pavlovic, D., Jevtovic-Stoimenov, T., Djordjevic, V., Milosevic, V.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1228
container_issue Suppl 2
container_start_page 1228
container_title Annals of the rheumatic diseases
container_volume 74
creator Basic, J.
Vojinovic, J.
Susic, G.
Pavlovic, D.
Jevtovic-Stoimenov, T.
Djordjevic, V.
Milosevic, V.
description BackgroundChronic inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus had been proven to have a higher risk of atherosclerosis and premature coronary artery disease. On the other hand, the role of inflammation on dyslipidemia in patients with juvenile idiopathic arthritis (JIA), is not yet well established.ObjectivesWe have investigated whether etanercept (tumor necrosis factor-α receptor blocking agent) has the influence on inflammation markers and lipid profile in patients with JIA, after 1 year of treatment.MethodsA total of 50 patients with active polyarticular JIA and 31 healthy children were enrolled in the study. JIA patients donated paired blood samples prior to and 12 months after etanercept therapy. Inflammation markers (erythrocite sedimentation rate (ESR), white blood cells count (WBC) and C-reactive protein (CRP) level), as well as serum cholesterol, triacylglycerol, LDL-C and HDL-C levels were determined using standard biochemical analysis.ResultsESR, WBC count and CRP levels were significanly higher in JIA patients before treatment in comparison to control (p=0.001, p=0.048, p
doi_str_mv 10.1136/annrheumdis-2015-eular.5544
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1901813226</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4322508325</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1276-8cdc4b5af7973ec99b0eb3eb5ab703e3fbef53094f309c0b9579f20e5825763</originalsourceid><addsrcrecordid>eNqVkMFKxDAQhoMouK6-Q8Bz16Rp2gZPq6y6sqKg95C2E5p1m9YkVTwIXnxRn8R214NXLzPMP_8_Ax9Cp5TMKGXpmbLW1dA3lfFRTCiPoN8oN-M8SfbQhCZpPsgp2UcTQgiLEpFmh-jI-_UwkpzmE_QxvyAi59-fX0814KXVmx5sCbjVeBGUBVdCF3BrtyvVNCqYYbhT7hmcx8pWeGU6U-EH12qzAWwsfhg8YIPHbybU-LZ_BTtulpVpOxVqU-K5C7UzwfhjdKDVxsPJb5-ix6vF0-VNtLq_Xl7OV1FB4yyN8rIqk4IrnYmMQSlEQaBgMChFRhgwXYDmjIhED6UkheCZ0DEBnsc8S9kUne6udq596cEHuW57Z4eHkgpCc8rieHSd71yla713oGXnTKPcu6REjrTlH9pypC23tOVIe0inu3TRrP8V_AGPzY1u</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901813226</pqid></control><display><type>article</type><title>AB0985 The Influence of Etanercept on Inflammation Markers and Lipid Profile in Patients with Juvenile Idiopathic Arthritis</title><source>BMJ Journals - NESLi2</source><creator>Basic, J. ; Vojinovic, J. ; Susic, G. ; Pavlovic, D. ; Jevtovic-Stoimenov, T. ; Djordjevic, V. ; Milosevic, V.</creator><creatorcontrib>Basic, J. ; Vojinovic, J. ; Susic, G. ; Pavlovic, D. ; Jevtovic-Stoimenov, T. ; Djordjevic, V. ; Milosevic, V.</creatorcontrib><description>BackgroundChronic inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus had been proven to have a higher risk of atherosclerosis and premature coronary artery disease. On the other hand, the role of inflammation on dyslipidemia in patients with juvenile idiopathic arthritis (JIA), is not yet well established.ObjectivesWe have investigated whether etanercept (tumor necrosis factor-α receptor blocking agent) has the influence on inflammation markers and lipid profile in patients with JIA, after 1 year of treatment.MethodsA total of 50 patients with active polyarticular JIA and 31 healthy children were enrolled in the study. JIA patients donated paired blood samples prior to and 12 months after etanercept therapy. Inflammation markers (erythrocite sedimentation rate (ESR), white blood cells count (WBC) and C-reactive protein (CRP) level), as well as serum cholesterol, triacylglycerol, LDL-C and HDL-C levels were determined using standard biochemical analysis.ResultsESR, WBC count and CRP levels were significanly higher in JIA patients before treatment in comparison to control (p=0.001, p=0.048, p&lt;0.001, respectively). Etanercept treatment significantly decreased ESR, WBC count and CRP levels in JIA patients in comparison to the values from before (p=0.011, p=0.039, p=0.016). Serum levels of cholesterol, triacylglycerol and LDL-C in JIA patients before treatment showed increase compared to control values (p=0.013, p=0.001, p=0.044). On the other hand HDL-C levels were lower in JIA patients in comparison to control (p&lt;0.001). Etanercept treatment significantly decreased triacylglycerol levels and increased HDL-C levels in JIA patients compared to baseline values (p=0.020, p=0.007). There is a negative correlation between ESR and HDL-C levels either before or after etanercept treatment (p=0.001, p=0.041).ConclusionsPatients with JIA showed disturbances in serum lipid profile. Etanercept treatment in JIA patients increased the levels of HDL-C and lowered triacylglycerol levels in comparison to baseline values.ReferencesKuo-Wei Yeh et al. PLoS One 2014;9(3):1-7.Breda L et al. Clin Res Cardiol 2013;102:63–71.Disclosure of InterestNone declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2015-eular.5544</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><ispartof>Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.1228-1228</ispartof><rights>2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2015 (c) 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/74/Suppl_2/1228.1.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/74/Suppl_2/1228.1.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,315,782,786,3198,23578,27931,27932,77608,77639</link.rule.ids></links><search><creatorcontrib>Basic, J.</creatorcontrib><creatorcontrib>Vojinovic, J.</creatorcontrib><creatorcontrib>Susic, G.</creatorcontrib><creatorcontrib>Pavlovic, D.</creatorcontrib><creatorcontrib>Jevtovic-Stoimenov, T.</creatorcontrib><creatorcontrib>Djordjevic, V.</creatorcontrib><creatorcontrib>Milosevic, V.</creatorcontrib><title>AB0985 The Influence of Etanercept on Inflammation Markers and Lipid Profile in Patients with Juvenile Idiopathic Arthritis</title><title>Annals of the rheumatic diseases</title><description>BackgroundChronic inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus had been proven to have a higher risk of atherosclerosis and premature coronary artery disease. On the other hand, the role of inflammation on dyslipidemia in patients with juvenile idiopathic arthritis (JIA), is not yet well established.ObjectivesWe have investigated whether etanercept (tumor necrosis factor-α receptor blocking agent) has the influence on inflammation markers and lipid profile in patients with JIA, after 1 year of treatment.MethodsA total of 50 patients with active polyarticular JIA and 31 healthy children were enrolled in the study. JIA patients donated paired blood samples prior to and 12 months after etanercept therapy. Inflammation markers (erythrocite sedimentation rate (ESR), white blood cells count (WBC) and C-reactive protein (CRP) level), as well as serum cholesterol, triacylglycerol, LDL-C and HDL-C levels were determined using standard biochemical analysis.ResultsESR, WBC count and CRP levels were significanly higher in JIA patients before treatment in comparison to control (p=0.001, p=0.048, p&lt;0.001, respectively). Etanercept treatment significantly decreased ESR, WBC count and CRP levels in JIA patients in comparison to the values from before (p=0.011, p=0.039, p=0.016). Serum levels of cholesterol, triacylglycerol and LDL-C in JIA patients before treatment showed increase compared to control values (p=0.013, p=0.001, p=0.044). On the other hand HDL-C levels were lower in JIA patients in comparison to control (p&lt;0.001). Etanercept treatment significantly decreased triacylglycerol levels and increased HDL-C levels in JIA patients compared to baseline values (p=0.020, p=0.007). There is a negative correlation between ESR and HDL-C levels either before or after etanercept treatment (p=0.001, p=0.041).ConclusionsPatients with JIA showed disturbances in serum lipid profile. Etanercept treatment in JIA patients increased the levels of HDL-C and lowered triacylglycerol levels in comparison to baseline values.ReferencesKuo-Wei Yeh et al. PLoS One 2014;9(3):1-7.Breda L et al. Clin Res Cardiol 2013;102:63–71.Disclosure of InterestNone declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqVkMFKxDAQhoMouK6-Q8Bz16Rp2gZPq6y6sqKg95C2E5p1m9YkVTwIXnxRn8R214NXLzPMP_8_Ax9Cp5TMKGXpmbLW1dA3lfFRTCiPoN8oN-M8SfbQhCZpPsgp2UcTQgiLEpFmh-jI-_UwkpzmE_QxvyAi59-fX0814KXVmx5sCbjVeBGUBVdCF3BrtyvVNCqYYbhT7hmcx8pWeGU6U-EH12qzAWwsfhg8YIPHbybU-LZ_BTtulpVpOxVqU-K5C7UzwfhjdKDVxsPJb5-ix6vF0-VNtLq_Xl7OV1FB4yyN8rIqk4IrnYmMQSlEQaBgMChFRhgwXYDmjIhED6UkheCZ0DEBnsc8S9kUne6udq596cEHuW57Z4eHkgpCc8rieHSd71yla713oGXnTKPcu6REjrTlH9pypC23tOVIe0inu3TRrP8V_AGPzY1u</recordid><startdate>201506</startdate><enddate>201506</enddate><creator>Basic, J.</creator><creator>Vojinovic, J.</creator><creator>Susic, G.</creator><creator>Pavlovic, D.</creator><creator>Jevtovic-Stoimenov, T.</creator><creator>Djordjevic, V.</creator><creator>Milosevic, V.</creator><general>BMJ Publishing Group LTD</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201506</creationdate><title>AB0985 The Influence of Etanercept on Inflammation Markers and Lipid Profile in Patients with Juvenile Idiopathic Arthritis</title><author>Basic, J. ; Vojinovic, J. ; Susic, G. ; Pavlovic, D. ; Jevtovic-Stoimenov, T. ; Djordjevic, V. ; Milosevic, V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1276-8cdc4b5af7973ec99b0eb3eb5ab703e3fbef53094f309c0b9579f20e5825763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Basic, J.</creatorcontrib><creatorcontrib>Vojinovic, J.</creatorcontrib><creatorcontrib>Susic, G.</creatorcontrib><creatorcontrib>Pavlovic, D.</creatorcontrib><creatorcontrib>Jevtovic-Stoimenov, T.</creatorcontrib><creatorcontrib>Djordjevic, V.</creatorcontrib><creatorcontrib>Milosevic, V.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Basic, J.</au><au>Vojinovic, J.</au><au>Susic, G.</au><au>Pavlovic, D.</au><au>Jevtovic-Stoimenov, T.</au><au>Djordjevic, V.</au><au>Milosevic, V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AB0985 The Influence of Etanercept on Inflammation Markers and Lipid Profile in Patients with Juvenile Idiopathic Arthritis</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2015-06</date><risdate>2015</risdate><volume>74</volume><issue>Suppl 2</issue><spage>1228</spage><epage>1228</epage><pages>1228-1228</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>BackgroundChronic inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus had been proven to have a higher risk of atherosclerosis and premature coronary artery disease. On the other hand, the role of inflammation on dyslipidemia in patients with juvenile idiopathic arthritis (JIA), is not yet well established.ObjectivesWe have investigated whether etanercept (tumor necrosis factor-α receptor blocking agent) has the influence on inflammation markers and lipid profile in patients with JIA, after 1 year of treatment.MethodsA total of 50 patients with active polyarticular JIA and 31 healthy children were enrolled in the study. JIA patients donated paired blood samples prior to and 12 months after etanercept therapy. Inflammation markers (erythrocite sedimentation rate (ESR), white blood cells count (WBC) and C-reactive protein (CRP) level), as well as serum cholesterol, triacylglycerol, LDL-C and HDL-C levels were determined using standard biochemical analysis.ResultsESR, WBC count and CRP levels were significanly higher in JIA patients before treatment in comparison to control (p=0.001, p=0.048, p&lt;0.001, respectively). Etanercept treatment significantly decreased ESR, WBC count and CRP levels in JIA patients in comparison to the values from before (p=0.011, p=0.039, p=0.016). Serum levels of cholesterol, triacylglycerol and LDL-C in JIA patients before treatment showed increase compared to control values (p=0.013, p=0.001, p=0.044). On the other hand HDL-C levels were lower in JIA patients in comparison to control (p&lt;0.001). Etanercept treatment significantly decreased triacylglycerol levels and increased HDL-C levels in JIA patients compared to baseline values (p=0.020, p=0.007). There is a negative correlation between ESR and HDL-C levels either before or after etanercept treatment (p=0.001, p=0.041).ConclusionsPatients with JIA showed disturbances in serum lipid profile. Etanercept treatment in JIA patients increased the levels of HDL-C and lowered triacylglycerol levels in comparison to baseline values.ReferencesKuo-Wei Yeh et al. PLoS One 2014;9(3):1-7.Breda L et al. Clin Res Cardiol 2013;102:63–71.Disclosure of InterestNone declared</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/annrheumdis-2015-eular.5544</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.1228-1228
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1901813226
source BMJ Journals - NESLi2
title AB0985 The Influence of Etanercept on Inflammation Markers and Lipid Profile in Patients with Juvenile Idiopathic Arthritis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-06T22%3A22%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AB0985%E2%80%85The%20Influence%20of%20Etanercept%20on%20Inflammation%20Markers%20and%20Lipid%20Profile%20in%20Patients%20with%20Juvenile%20Idiopathic%20Arthritis&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Basic,%20J.&rft.date=2015-06&rft.volume=74&rft.issue=Suppl%202&rft.spage=1228&rft.epage=1228&rft.pages=1228-1228&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2015-eular.5544&rft_dat=%3Cproquest_cross%3E4322508325%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901813226&rft_id=info:pmid/&rfr_iscdi=true